ClinicalTrials.gg

Program

hafnium oxide

Also written as “JNJ-90301900”, “PEP503” and “JNJ-90301900 (NBTXR3)”.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Carcinoma, Non-Small-Cell Lung · Rectal Neoplasms, led by 3 companies.

Furthest: phase 3, since May 4, 20216 company-led studies, 4 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson33 open or runningphase 3since May 4, 2021May 4, 2021Jun 30, 2028phase 3 · NCT04892173
PharmaEngine20 open or runningphase 2since Jun 1, 2015Jun 1, 2015none ahead
Nanobiotix11 open or runningphase 1since Apr 10, 2018Apr 10, 2018Apr 30, 2027phase 1 · NCT03589339
  • Named in Johnson & Johnson’s own pipeline as JNJ-1900 (NBTXR3), phase 3, as of Oct 13, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 1, 2015First study: phase 2 study in Rectal NeoplasmsNew to PharmaEnginePharmaEngine · NCT02465593 · 32 enrolled · Taiwan
  2. Aug 31, 2016Phase 2 study in Squamous Cell Carcinoma of Head and NeckPharmaEngine · NCT02901483 · 12 enrolled · Taiwan
  3. Apr 10, 2018Nanobiotix's first study: phase 1 study in Squamous Cell Carcinoma of Head and NeckNew to NanobiotixNanobiotix · NCT03589339 · 145 enrolled · United States
  4. May 4, 2021Johnson & Johnson's first study: phase 3 study in Carcinoma, Squamous CellNew to Johnson & JohnsonJohnson & Johnson · NCT04892173 · 500 planned · United States, Austria, Belgium and more
  5. Oct 30, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667908 · 130 planned · United States, Australia, Brazil and more
  6. Oct 17, 2025Phase 1 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT07219212 · 45 planned · United States, France, Japan and more

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNanobiotix · NCT03589339
  2. Jun 30, 2028Primary completion: phase 3 study in Carcinoma, Squamous CellJohnson & Johnson · NCT04892173
  3. Jul 14, 2028Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckJohnson & Johnson · NCT07219212
  4. Dec 31, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT06667908

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07219212Squamous Cell Carcinoma of Head and Neck · United States, France, Japan and more1RecruitingJohnson & JohnsonJul 14, 202845
NCT06667908Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more2RecruitingJohnson & JohnsonDec 31, 2028130
NCT04892173Carcinoma, Squamous Cell · United States, Austria, Belgium and more3RecruitingJohnson & JohnsonJun 30, 2028500
NCT03589339Squamous Cell Carcinoma of Head and Neck · United States1Active, not recruitingNanobiotixApr 30, 2027145
NCT02901483Squamous Cell Carcinoma of Head and Neck · Taiwan2TerminatedPharmaEngineAug 17, 202012
NCT02465593Rectal Neoplasms · Taiwan2TerminatedPharmaEngineJul 28, 202132

How it is read

Names in the registry

  • “JNJ-90301900”, 2 entries
  • “PEP503”, 2 entries
  • “JNJ-90301900 (NBTXR3)”, 1 entry
  • “NBTXR3”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
hafnium oxide (Johnson & Johnson): development program | ClinicalTrials.gg